References
- World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575–82
- World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582–88
- Jick H., Jick S. S., Gurewich V., Myers M. W., Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589–93
- Bloemenkamp K. W.M., Rosendaal F. R., Helmerhorst F. M., Büller H. R., Vandenbroucke J. P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen. Lancet 1995; 346: 1593–96
- Spitzer W. O., Lewis M. A., Heinemann L. A., Thorogood M., MacRae K. D. Third generation oral contraceptives and risk of venous thromboembolic disorders: and international case-control study. Br. Med. J. 1996; 312: 83–8
- The writing committee for the Second European Conference on Sex Steroids and Metabolism. Consensus Statement of the Consensus development meeting 1995; combined oral contraceptives and cardiovascular disease. Gynecol. Endocrinol. 1996; 10: 1–5